NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
MobiKwik to Transfer LSP Business to Subsidiary and Amend MoA for Payment Aggregator Services
One MobiKwik Systems Limited is seeking shareholder approval to transfer its Lending Services Provider (LSP) business to its wholly-owned subsidiary, MobiKwik Distribution Services Private Limited (MDSPL), via a slump sale at book value. Additionally, the company proposes to amend its Memorandum of Association to formally include payment aggregator and gateway services, aligning with RBI regulatory requirements. The e-voting process for these special resolutions will take place between June 03, 2026, and July 02, 2026.
முக்கிய அம்சங்கள்
Proposed slump sale of the Lending Services Provider (LSP) business to wholly-owned subsidiary MDSPL at book value.Amendment of the Memorandum of Association to include sub-clause (10) for payment aggregator, gateway, and intermediary services.The restructuring aims to streamline operations and ensure compliance with Reserve Bank of India (RBI) guidelines for fintechs.Remote e-voting period is set from June 03, 2026, to July 02, 2026, with results to be declared within two working days.The LSP business transfer includes all tangible/intangible assets, licenses, personnel, and contracts on an 'as is where is' basis.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strategic move to ring-fence the lending business and formalize the payment aggregator vertical, which could improve regulatory clarity. Monitor the completion of the slump sale and its impact on the consolidated financial structure.
Bigbloc Construction Q4 FY26: Revenue Grows 35% to ₹87 Cr; Reports Net Loss of ₹1 Cr
Bigbloc Construction reported a robust 35% YoY revenue growth in Q4 FY26 to ₹87 crore, supported by a 40% increase in sales volumes. However, the company faced severe margin compression, with full-year EBITDA margins falling to 6.21% from 13% in FY25 due to elevated input costs and pricing pressure. Despite the top-line growth, the company posted a net loss of ₹1 crore for the quarter and ₹9 crore for the full year FY26. Management is targeting 10-20% volume growth in FY27, banking on high-margin AAC wall panels and construction chemicals to drive recovery.
முக்கிய அம்சங்கள்
Sales volume for Q4 FY26 surged 40% YoY to 2,45,870 cubic meters, with full-year volume up 37%.EBITDA margins for FY26 dropped to 6.21% from 13% in FY25, primarily due to a 5-6% drop in realizations and higher operating costs.The company reported a net loss of ₹9 crore for FY26 on a total revenue of ₹283 crore.New high-margin segments like AAC wall panels (30-45% EBITDA) and construction chemicals (25-30% EBITDA) are expected to contribute significantly to future revenue.Bigbloc has accumulated 150,000 tons of carbon credits valued at $2-$3 per ton, which are expected to be monetized soon.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the company's ability to improve capacity utilization and pass on rising input costs to customers. While volume growth is strong, the transition back to profitability depends on the successful scaling of the high-margin AAC panel and construction chemical divisions.
Biocon Reduces Net Debt/EBITDA to 2.7x; Integrates Biosimilars for $200B Market Opportunity
Biocon has successfully integrated the Viatris biosimilar acquisition and is consolidating its business structure, now holding 99.2% of Biocon Biologics. The company significantly improved its financial health, reducing Net Debt/EBITDA from 4.3x in FY23 to 2.7x in FY26 through a ₹4,500 Cr QIP and $1.2B refinancing. With FY26 revenues at $1,924M and a portfolio of 30+ biosimilars, the company is transitioning from a heavy investment phase to a growth-focused integrated biopharma entity. Major CapEx is largely complete, and the company expects ₹300 Cr in annual interest savings from its recent debt restructuring.
முக்கிய அம்சங்கள்
Reduced Net Debt/EBITDA from 4.3x (FY23) to 2.7x (FY26) through systemic debt reduction and robust EBITDA growth.Raised ₹4,500 Cr via QIP to redeem structured instruments, resulting in projected annual interest savings of ₹300 Cr.Consolidated Biocon Biologics ownership to 99.2%, with board approval to acquire the remaining 0.8% for full control.Reported FY26 revenues of $1,924M, with Biosimilars contributing 60% and CRDMO services contributing 22%.Pipeline includes 30+ biosimilars and 3 GLP-1s targeting a total addressable market of over $200B.
👀 கவனிக்க வேண்டியவை
Investors should view the successful deleveraging and business consolidation as a significant de-risking event. Focus should now shift to the commercial execution of the biosimilar pipeline and the margin expansion expected from reduced interest costs.
Ambica Agarbathies FY26 PAT Jumps to ₹3.45 Cr; Board Approves ₹2.04 Cr Preferential Issue
Ambica Agarbathies reported a strong recovery in profitability for the fiscal year ended March 31, 2026, with Net Profit (PAT) rising to ₹344.74 Lakhs from ₹48.86 Lakhs in the previous year. Total income for FY26 grew to ₹14,954.02 Lakhs, driven primarily by the Agarbathies division which contributed ₹11,583.75 Lakhs. The Board also approved a preferential allotment of 8,48,600 equity shares to the promoter group at ₹24 per share (including a ₹14 premium) to raise approximately ₹2.04 Crores. An Extra Ordinary General Meeting (EGM) is scheduled for June 30, 2026, to obtain shareholder approval for this fundraise.
முக்கிய அம்சங்கள்
Annual Net Profit (PAT) surged significantly to ₹344.74 Lakhs in FY26 compared to ₹48.86 Lakhs in FY25.Total Income for the full year increased by 16% year-on-year to ₹14,954.02 Lakhs.Board approved a preferential issue of 8,48,600 equity shares to four promoter group members at ₹24 per share.The Agarbathies division remains the core business, generating ₹11,583.75 Lakhs in revenue for the year.Q4 FY26 showed a turnaround with a PAT of ₹81.59 Lakhs versus a loss of ₹193.53 Lakhs in the same quarter last year.
👀 கவனிக்க வேண்டியவை
Investors should view the sharp increase in net profit and the promoter's capital infusion as positive signals of operational recovery and management confidence. Monitor the upcoming EGM on June 30 for the formal approval of the preferential allotment.
Panacea Biotec FY26: Consolidated Revenue up 14%, Net Loss narrows to ₹7.16 Cr
Panacea Biotec reported a 14% increase in consolidated total income to ₹656.67 crore for FY26, while the consolidated net loss narrowed slightly to ₹7.16 crore from ₹8.72 crore in FY25. However, standalone performance was weaker, with the net loss widening significantly to ₹29.88 crore from ₹15.23 crore in the previous year. Due to persistent losses, the company has skipped dividend payments for the fiscal year and appointed Mr. Rajinder Singh Manku as an Independent Director.
முக்கிய அம்சங்கள்
Consolidated total income rose 13.3% YoY to ₹65,667 Lakh in FY26.Consolidated net loss narrowed to ₹716 Lakh from ₹872 Lakh in FY25.Standalone net loss widened to ₹2,988 Lakh compared to ₹1,523 Lakh in the previous year despite revenue growth.The Board decided to pass over dividends for FY26 on account of losses.Mr. Rajinder Singh Manku appointed as Independent Director for a 5-year term effective July 1, 2026.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company continues to report losses at both standalone and consolidated levels. Monitor if the double-digit revenue growth can eventually lead to a turnaround in bottom-line profitability.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
SBI Cards Appoints Saurav Ghosh as COO for 2 Years; Ashutosh Sharma to Step Down
SBI Cards and Payment Services has announced the appointment of Mr. Saurav Ghosh as the new Chief Operating Officer (COO) for a fixed term of 2 years, effective June 21, 2026. He will succeed the outgoing COO, Mr. Ashutosh Kumar Sharma, whose term concludes at the close of business hours on June 20, 2026. Mr. Ghosh brings over 24 years of extensive experience in banking operations, credit management, and digital transformation to the role. The transition was approved by the Board of Directors following recommendations from the Nomination and Remuneration Committee.
முக்கிய அம்சங்கள்
Mr. Saurav Ghosh appointed as Chief Operating Officer for a 2-year term starting June 21, 2026.Outgoing COO Mr. Ashutosh Kumar Sharma to demit office on June 20, 2026, following the completion of his tenure.New appointee Mr. Ghosh has over 24 years of experience across banking operations, HR, and regulatory compliance.The Board meeting approving the change commenced at 4:00 p.m. and concluded at 5:52 p.m. on May 30, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a planned leadership transition and monitor if the new COO introduces any significant shifts in operational efficiency or digital strategy.
Biofil Chemicals FY26 Net Profit Jumps 400% to ₹2.78 Cr Driven by Other Income
Biofil Chemicals reported a significant 399% increase in annual net profit to ₹278.60 lakhs for FY26, compared to ₹55.78 lakhs in FY25. This surge was primarily driven by a massive spike in 'Other Income' which reached ₹308.23 lakhs, while core revenue from operations actually declined by 15% YoY to ₹2839.52 lakhs. For the fourth quarter (Q4 FY26), the company recorded a net profit of ₹21.22 lakhs on revenue of ₹756.56 lakhs. Despite the revenue drop, the company managed to reduce its total annual expenses by 15% to ₹2802.79 lakhs.
முக்கிய அம்சங்கள்
Annual net profit surged to ₹278.60 lakhs in FY26 from ₹55.78 lakhs in FY25.Other Income spiked to ₹308.23 lakhs in FY26, up from just ₹30.52 lakhs in the previous year.Revenue from operations for FY26 decreased by 15% to ₹2839.52 lakhs compared to ₹3340.22 lakhs in FY25.Total annual expenses were reduced to ₹2802.79 lakhs from ₹3297.13 lakhs YoY.Q4 FY26 revenue stood at ₹756.56 lakhs with a net profit of ₹21.22 lakhs.
👀 கவனிக்க வேண்டியவை
Investors should be cautious as the profit growth is largely attributed to non-operational 'Other Income' rather than core business growth. It is advisable to investigate the source of this other income and monitor if the company can reverse the declining trend in its core operational revenue.
Concord Biotech FY26 PAT drops 30% to ₹259 Cr amid global headwinds and procurement delays
Concord Biotech reported a challenging FY26 with consolidated revenue declining 12% YoY to ₹1,054.9 crore and PAT falling 30% to ₹259.2 crore. EBITDA margins saw significant compression, dropping to 34.8% from 42.2% in the previous year, primarily due to geopolitical tensions in the Middle East and a shift in US procurement patterns from bulk to staggered orders. Despite the financial dip, the company successfully commercialized its injectable facility and established a US subsidiary, Stellon Biotech, to strengthen its global footprint.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 decreased by 12% YoY to ₹1,054.9 crore compared to ₹1,200.1 crore in FY25.Full-year EBITDA margin contracted by 736 bps to 34.8%, while Q4FY26 margin stood at 36.4%.Net Profit (PAT) for the year declined by 30% YoY to ₹259.2 crore from ₹371.6 crore.API segment remains the primary driver contributing 79% of total revenue, with formulations at 21%.Management identified specific headwinds including a 3-month delay in EU regulatory confirmations and US Veterans Affairs tender delays.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution due to the significant margin contraction and revenue decline, though management's optimism for an FY27 recovery backed by new injectable and soft gel facilities warrants a 'watch' for signs of turnaround in the next two quarters.
Concord Biotech Recommends ₹7.55 Dividend and Approves FY26 Financial Results
Concord Biotech's Board has recommended a final dividend of ₹7.55 per equity share for the financial year ended March 31, 2026. The company reported audited financial results for both standalone and consolidated entities with an unmodified audit opinion from BSR & Co. LLP. To strengthen governance, the board appointed Mrs. Ekta Gupta as an Additional Independent Director for a five-year term. The record date for the dividend payout is set for July 24, 2026, subject to shareholder approval.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26.Fixed July 24, 2026, as the record date for identifying shareholders eligible for the dividend payout.Appointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026.Statutory auditors issued an unmodified opinion on the standalone and consolidated financial results for FY26.Appointed Manubhai & Shah LLP and Dalwadi & Associates as Internal and Cost Auditors respectively for FY27.
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold the shares by the record date of July 24, 2026, to qualify for the ₹7.55 dividend. The clean audit report and addition of an independent director reflect stable corporate governance.
Tasty Bite FY26 PAT Jumps 38% to ₹353M; Company Becomes Debt-Free with ₹10 Dividend
Tasty Bite Eatables reported a flat revenue of ₹5,716 million for FY26, but achieved a significant 38% growth in Profit After Tax (PAT) to ₹353 million. The company successfully transitioned to a debt-free status after repaying all borrowings and proposed a 100% dividend of ₹10 per share, which is five times higher than the previous year. While the US affiliate business declined by 40% due to macroeconomic headwinds, the Mars Affiliate business surged by 148% and the Food Service segment grew by 18%. Operational efficiencies led to a 250 bps expansion in EBITDA margins to 14.8%, despite increased spending on brand building.
முக்கிய அம்சங்கள்
FY26 Profit After Tax (PAT) increased by 38% YoY to ₹353 million, driven by higher EBITDA and lower interest costs.EBITDA margins expanded by 250 bps to 14.8% through operational efficiencies and strict control on fixed costs.The company is now fully debt-free after repaying all borrowings and has proposed a dividend of ₹10 per share.Food Service business recorded its 10th consecutive quarter of growth, rising 18% in FY26.Mars Affiliate business grew 148% YoY, helping offset a 40% decline in the PBI US Affiliate segment caused by US tariff challenges.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the company's debt-free status and significant margin expansion despite flat top-line growth. The strategic pivot toward domestic food services and quick-commerce platforms like Zepto offers a promising hedge against volatile US export revenues.
Tasty Bite Declares Rs 10 Dividend; Auditor Issues Qualified Opinion Over Related Party Transactions
Tasty Bite Eatables has recommended a final dividend of Rs 10 per share for FY26, despite reporting a qualified audit opinion. The company reported a total income of INR 5,716.22 million and a net profit of INR 353.02 million for the fiscal year. However, a major governance concern has emerged as shareholders rejected post-facto approval for material related party transactions exceeding thresholds by INR 94.47 million. The auditor has expressed inability to determine the consequential effects of this shareholder dissent on the financial statements.
முக்கிய அம்சங்கள்
Recommended a final dividend of Rs 10 per equity share for the financial year ended March 31, 2026.Reported annual total income of INR 5,716.22 million and net profit of INR 353.02 million.Auditors issued a qualified opinion regarding unauthorized related party transactions totaling approximately INR 143.39 million.Shareholders officially dissented and rejected the postal ballot for post-facto approval of material related party transactions.Earnings Per Share (EPS) for the full year was reported at INR 137.57.
👀 கவனிக்க வேண்டியவை
While the dividend is a positive yield event, the shareholder rejection of related party transactions and the qualified audit opinion are significant governance red flags. Investors should wait for management's clarification on how they intend to resolve the unauthorized transactions before making new commitments.
Gufic Biosciences Q4 Net Profit Surges 184% YoY to ₹21.9 Cr; FY26 Revenue Up 15%
Gufic Biosciences reported a robust Q4 FY26 performance with consolidated revenue growing 22.8% YoY to ₹251.8 crore and net profit jumping 183.6% to ₹21.9 crore. For the full financial year 2025-26, revenue increased by 15.1% to ₹944 crore, although annual net profit saw a slight decline of 7.8% to ₹64.2 crore due to increased finance and depreciation costs. The company has recommended a final dividend of ₹0.10 per share. A significant increase in inventory and short-term borrowings was observed, which impacted the operating cash flow for the year.
முக்கிய அம்சங்கள்
Q4 FY26 consolidated revenue rose 22.8% YoY to ₹251.82 crore from ₹205.02 crore.Q4 FY26 net profit surged 183.6% YoY to ₹21.90 crore compared to ₹7.72 crore in the previous year's quarter.Full-year FY26 revenue reached ₹944.01 crore, up from ₹819.81 crore in FY25.Recommended a final dividend of ₹0.10 per equity share (10% of face value).Short-term borrowings increased significantly to ₹280.13 crore from ₹179.88 crore YoY.
👀 கவனிக்க வேண்டியவை
The strong Q4 recovery indicates a positive turnaround in operational performance; however, investors should monitor the rising debt levels and inventory buildup which have pressured cash flows. The stock remains a 'Watch' to see if the Q4 margin expansion is sustainable into the next fiscal year.
BIL Vyapar Reports FY26 Results Under CIRP; Auditors Issue Disclaimer of Opinion
BIL Vyapar Limited (formerly Binani Industries) has released its FY26 financial results while undergoing Corporate Insolvency Resolution Process (CIRP). The statutory auditors have issued a Disclaimer of Opinion, stating they could not obtain sufficient evidence to provide a basis for an audit opinion. The company's net worth is completely eroded with accumulated losses of INR 21,766.17 lakhs, and current liabilities exceed current assets by INR 18,627.68 lakhs. Consequently, the financial statements have been prepared on a liquidation basis rather than as a going concern.
முக்கிய அம்சங்கள்
Auditors issued a Disclaimer of Opinion for FY26 due to lack of evidence on asset valuations and liabilities.Accumulated losses reached INR 21,766.17 lakhs, resulting in total erosion of net worth.Current liabilities exceed current assets by INR 18,627.68 lakhs as of March 31, 2026.Financials are prepared on a liquidation basis as the 'going concern' assumption is no longer valid.Outstanding corporate guarantees of INR 8,025 lakhs for Edayar Zinc Limited remain a significant admitted claim.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency proceedings and the auditors cannot verify the financial statements. The preparation of accounts on a liquidation basis indicates a high risk that equity shareholders may receive little to no value during the resolution process.
Biocon Revises Preferential Issue Price to ₹376.41 and Sets Swap Ratio for Biologics Unit
Biocon Limited has issued a corrigendum to its May 07, 2026, Postal Ballot Notice regarding a preferential issue of equity shares for non-cash consideration. The company will issue 8,786,362 shares to acquire stakes from Biocon Biologics Limited (BBL) shareholders. Following stock exchange feedback, the floor price is now ₹373.08, with an issue price of ₹376.41 per share. The revised swap ratio is approximately 76.16 Biocon Ltd shares for every 100 BBL shares held by the selling shareholders.
முக்கிய அம்சங்கள்
Issuance of 87,86,362 equity shares on a preferential basis for consideration other than cashRevised issue price fixed at ₹376.41 per share based on updated valuation methodologySwap ratio set at 0.76159 Biocon Ltd shares for every 100 Biocon Biologics Limited sharesFloor price determined at ₹373.08 based on 90-day volume weighted average price (VWAP)The transaction consolidates ownership in the Biologics subsidiary by acquiring shares from various individual stakeholders
👀 கவனிக்க வேண்டியவை
Investors should monitor the impact of the 8.78 million share dilution against the long-term benefit of consolidating the Biologics business. No immediate action is required as this is a technical adjustment to a previously announced corporate action.
SBI Life Appoints Ramesh Venkateshamurthy as Deputy CEO Effective May 29, 2026
SBI Life Insurance has appointed Mr. Ramesh Venkateshamurthy as the new Deputy Chief Executive Officer, effective May 29, 2026. Mr. Venkateshamurthy transitions from State Bank of India (SBI), where he most recently served as General Manager (Yono Retail) & UPI since June 2023. His extensive background in digital banking and customer experience at SBI is expected to bolster SBI Life's digital transformation initiatives. The appointment follows a recommendation by the Board Nomination and Remuneration Committee.
முக்கிய அம்சங்கள்
Mr. Ramesh Venkateshamurthy appointed as Deputy CEO effective May 29, 2026.Served as General Manager (Yono Retail) & UPI at SBI, managing the bank's UPI portfolio since June 2023.Previously held the position of Deputy General Manager - Customer Experience at SBI's Corporate Centre.Brings significant experience in digital marketing and propagating digital banking products through various channels.
👀 கவனிக்க வேண்டியவை
Investors should monitor how the new Deputy CEO's digital expertise influences SBI Life's direct-to-customer digital sales and operational efficiency. No immediate portfolio changes are recommended based on this leadership update.
Concord Biotech Recommends ₹7.55 Dividend; Appoints New Independent Director
Concord Biotech's board has recommended a final dividend of ₹7.55 per share for FY 2025-26, subject to shareholder approval. The company reported audited financial results for the year ended March 31, 2026, receiving a clean, unmodified opinion from its statutory auditors. In a move to strengthen governance, Mrs. Ekta Gupta has been appointed as an Additional Independent Director for a five-year term. The board also finalized the appointment of new internal and cost auditors for the 2026-27 fiscal year.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹7.55 per equity share of face value ₹1 each for FY 2025-26Fixed July 24, 2026, as the record date for identifying eligible shareholders for dividend paymentAppointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term starting June 1, 2026Statutory auditors BSR & Co. LLP issued an unmodified audit opinion for the FY26 financial resultsAppointed M/s. Manubhai & Shah LLP as Internal Auditor for the financial year 2026-27
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold the stock before the July 24, 2026, record date to be eligible for the ₹7.55 dividend. The clean audit report and board expansion are positive indicators of corporate governance and stability.
Concord Biotech Recommends ₹7.55 Final Dividend; Sets Record Date for July 2026
Concord Biotech Limited has recommended a final dividend of ₹7.55 per equity share for the financial year 2025-26. The board has fixed July 24, 2026, as the record date to determine shareholder eligibility for the payout, pending approval at the upcoming Annual General Meeting. In addition to the dividend, the company reported audited financial results for FY26 with an unmodified audit opinion from BSR & Co. LLP. The board also strengthened its governance by appointing Mrs. Ekta Gupta as an Additional Independent Director for a five-year term.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹7.55 per equity share of face value ₹1 for FY 2025-26Fixed July 24, 2026, as the record date for identifying eligible shareholders for the dividendAppointed Mrs. Ekta Gupta as an Additional Independent Director for a 5-year term effective June 1, 2026Statutory auditors issued an unmodified opinion on both standalone and consolidated financial results for FY26Approved the appointment of Manubhai & Shah LLP as Internal Auditors and Dalwadi & Associates as Cost Auditors for FY 2026-27
👀 கவனிக்க வேண்டியவை
Investors seeking dividend income should ensure they hold shares before the July 24, 2026 record date. The unmodified audit report and board expansion reflect positive corporate governance and financial stability.
Rubicon Research Recommends Final Dividend of ₹1.50 per Share for FY26
Rubicon Research Limited's Board of Directors has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026. This dividend is calculated on a face value of ₹1 per share, representing a 150% payout ratio relative to the face value. The announcement was made alongside the approval of the company's audited financial results for the quarter and full year. The final payout is subject to shareholder approval at the upcoming Annual General Meeting and will be distributed within 30 days of declaration.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026Dividend is based on a face value of ₹1.00 per share, reflecting a 150% dividend rateAudited financial results for Q4 and FY26 approved with an unmodified opinion from Deloitte Haskins & Sells LLPDividend payment to be completed within 30 days from the date of declaration at the Annual General Meeting
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of the record date to ensure eligibility for the ₹1.50 per share dividend. The unmodified audit report provides additional assurance regarding the company's financial disclosures.
Rubicon Research Recommends ₹1.50 Dividend and Approves ESOP Scheme 2026
Rubicon Research Limited has approved its audited financial results for the quarter and year ended March 31, 2026, with an unmodified auditor's opinion. The Board has recommended a final dividend of ₹1.50 per equity share (150% of face value), pending shareholder approval at the upcoming AGM. Additionally, the company is moving forward with the 'Employees Stock Option Scheme 2026' to incentivize and retain talent across its global operations.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹1.50 per equity share of face value ₹1 for FY 2025-26.Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.Statutory auditors Deloitte Haskins & Sells LLP issued a clean, unmodified opinion on the financial statements.Formulated and adopted the 'Rubicon Research Limited - Employees Stock Option Scheme 2026'.Consolidated results include performance from 13 global subsidiaries across the US, Canada, Singapore, and Europe.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming Annual General Meeting for dividend declaration and review the full financial statement for year-on-year growth metrics. The introduction of the ESOP scheme is a positive indicator of management's focus on long-term human capital stability.
Rubicon Research Q4 PAT Surges 112% to ₹76.8 Cr; Revenue Up 43.5% YoY
Rubicon Research reported robust Q4 FY26 results with revenue growing 43.5% YoY to ₹513.9 crore and PAT doubling to ₹76.8 crore. The company maintained strong EBITDA margins of 23.6% despite increased reliance on outsourced manufacturing due to capacity constraints. Significant progress was made in debt reduction using IPO proceeds, and the acquisition of Arinna Lifesciences marks a strategic entry into the Indian CNS market. With 24 products under USFDA review and 12 approvals received in FY26, the growth trajectory remains strong.
முக்கிய அம்சங்கள்
Q4 FY26 Revenue grew 43.5% YoY to ₹5,139 million; PAT surged 111.8% to ₹768 million.Full-year FY26 Revenue reached ₹17,540 million with an 83.6% growth in PAT to ₹2,467 million.Board recommended a 150% dividend (₹1.50 per share) for the financial year.Utilized IPO proceeds to repay ₹265 crore of debt, improving the debt-to-equity profile.Acquired 85% stake in Arinna Lifesciences for ₹176 crore to establish a domestic CNS market presence.
👀 கவனிக்க வேண்டியவை
The company shows high R&D productivity (5.9x revenue multiple) and a strong product pipeline, making it a compelling growth story. Investors should monitor the Pithampur facility's USFDA inspection as its ramp-up in Q1 CY27 is expected to be margin accretive.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
